FDA 483 - Asphar Research Labs Private Limited - July 17, 2024

An FDA inspection of Asphar Research Labs Private Limited, a contract testing laboratory in Hyderabad, India, conducted from July 15-17, 2024, revealed significant observations related to their quality control unit and operational procedures. The firm received a Form FDA 483 detailing these deficiencies.

Key issues included the quality control unit's failure to adequately establish and follow written procedures. An analyst was observed inconsistently averaging assay results and using different fill weight calculations for stability samples, deviating from approved test methods without conducting proper investigations. This practice compromises data integrity and adherence to validated analytical procedures.

Further observations highlighted the quality unit's inadequate investigation into potential equipment defects, specifically water condensation on an accelerated stability chamber. The vendor's explanation for this issue lacked a thorough root cause analysis. Additionally, the standard operating procedure for monitoring stability chambers was found deficient, as it failed to ensure traceability of sample loading and unloading through an audit trail, impacting the reliability of stability study data.

These findings indicate a need for enhanced compliance with Current Good Manufacturing Practices (CGMP) to ensure the consistent quality and safety of prescription drug products. Asphar Research Labs is expected to address these observations by implementing comprehensive corrective and preventive actions to strengthen their quality management system.